España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Astellas Pharma
ALPMF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$10.27
0.72
7.54%
At close: -
$10.87
0.60
5.79%
After Hours: Mar 12, 9:18 AM EDT
Get Report
Comment
Astellas Pharma (ALPMF) Forecast
News
Earnings
Astellas Pharma (ALPMF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Astellas Pharma (OTC:ALPMF) Stock
Astellas Pharma Stock (OTC: ALPMF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, October 16, 2024
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
Vandana Singh
Monday, August 05, 2024
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Vandana Singh
Friday, May 17, 2024
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Vandana Singh
Friday, November 17, 2023
Astellas Pharma And Pfizer Announced FDA Appr...
Benzinga Newsdesk
Thursday, October 05, 2023
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
Vandana Singh
Friday, September 22, 2023
Why Is Seagen Stock Trading Higher Today?
Vandana Singh
Wednesday, September 20, 2023
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
Vandana Singh
Wednesday, August 23, 2023
Pfizer And Astellas Pharma Report FDA Grants ...
Benzinga Newsdesk
Thursday, July 06, 2023
On July 6, At Special Meeting Iveric Bio Inc Board Of Directors Approved Merger Proposal With Astellas Pharma
Happy Mohamed
Thursday, June 08, 2023
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
Vandana Singh
Tuesday, May 30, 2023
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
David Willey
-
Sponsored
Monday, May 15, 2023
Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
Vandana Singh
Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
Vandana Singh
Monday, May 01, 2023
Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
Vandana Singh
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
Vandana Singh
Tuesday, April 04, 2023
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
Vandana Singh
Tuesday, March 28, 2023
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
Vandana Singh
Monday, March 27, 2023
Japanese Government Urges China To Release Astellas Pharma's Employee
Vandana Singh
Friday, March 17, 2023
Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
Vandana Singh
Tuesday, January 31, 2023
Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts
Vandana Singh
Tuesday, January 24, 2023
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Vandana Singh
Tuesday, October 25, 2022
Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs
Vandana Singh
Thursday, August 18, 2022
Astellas' Menopause Drug Under FDA Review
Vandana Singh
Tuesday, July 26, 2022
Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say
Vandana Singh
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Vandana Singh
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial
Vandana Singh
Tuesday, June 28, 2022
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Vandana Singh
Sutro Biopharma Stock Surges On Cancer Treatment Pact
Vandana Singh
Monday, June 27, 2022
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Vandana Singh
Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold
Vandana Singh
Monday, May 09, 2022
Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies
Vandana Singh
Wednesday, April 13, 2022
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer
Vandana Singh
Tuesday, March 15, 2022
Astellas' Menopause Drug Suffers Setback After Failed Asian Trial
Vandana Singh
Monday, March 07, 2022
Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing
Vandana Singh
Tuesday, February 15, 2022
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
Vandana Singh
Thursday, December 02, 2021
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
Vandana Singh
Monday, September 27, 2021
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
Vandana Singh
Tuesday, September 14, 2021
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Vandana Singh
Wednesday, September 01, 2021
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
Vandana Singh
Friday, August 20, 2021
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
Vandana Singh
Wednesday, August 11, 2021
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
Vandana Singh
Monday, July 19, 2021
Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data
Vandana Singh
Monday, July 12, 2021
Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer
Vandana Singh
Tuesday, May 11, 2021
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
Vandana Singh
Monday, May 03, 2021
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
Vandana Singh
Tuesday, April 27, 2021
Astellas Takes $540M Impairment Charge Of $3B Audentes Buyout On Gene Therapy Trial Hold
Vandana Singh
Wednesday, April 07, 2021
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat
Vandana Singh
Thursday, March 11, 2021
Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer
Vandana Singh
Friday, February 19, 2021
Astellas Pharma's Fezolinetant Topped Placebo For Reducing Severity Of Menopausal Hot Flash In Phase 3 Studies
Vandana Singh
Thursday, February 18, 2021
Seagen/Astellas Pharma Seek Approval For PADCEV's Expanded Use In Urothelial Cancer Settings
Vandana Singh
Show More